addex Therapeutics

Innovative Treatments for Central Nervous System Disorders

May 2026

Allosteric modulators for human health

Disclaimer

These materials do not constitute or form part, or all, of any offer or invitation to sell or issue, neither in the United States of America nor elsewhere, or any solicitation of any offer to purchase or subscribe for, any securities, nor shall part, or all, of these materials or their distribution form the basis of, or be relied on in connection with, any contract or investment decision in relation to any securities.

These materials contain forward-looking statements based on the currently held beliefs and assumptions of the management of Addex Therapeutics, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of Addex Therapeutics Ltd, or industry results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements.

Given these risks, uncertainties and other factors, recipients of this document are cautioned not to place undue reliance on these forward-looking statements. Addex Therapeutics Ltd disclaims any obligation to update these forward-looking statements to reflect future events or developments.

Addex Overview

High value programs reaching significant milestones	➢ GABAB PAM for cough ready to enter IND enabling studies ➢ Dipraglurant for post-stroke/TBI[1] recovery – Phase 2 ready ➢ Neurosterix portfolio : M4 PAM in Phase 1 & mGlu7 NAM in IND enabling studies ➢ Investment in Stalicla, clinical stage precision medicine neurodevelopmental disorder company
20% equity interest in spin-out company, Neurosterix	➢ Leading allosteric modulator drug discovery platform – Validated & differentiated pharmacological approach ➢ Preclinical portfolio of high value programs – Lead program: M4 PAM for schizophrenia expected to complete Phase 1 in May 2026 ➢ $65M series A financing in April 2024 led by Perceptive Advisors
High value industry partnership driving future value	➢ GABAB PAM for SUD[2] partnered with Indivior - IND enabling studies successfully completed – ready to start Phase 1 – $330M in milestones & tiered royalties from high single digit to low double digit
Strong balance sheet	➢ Dual listed on SIX Swiss Exchange & US Nasdaq Capital Market ➢ CHF 1.6M ($2.0M) cash at December 31, 2025 ➢ Cash runway through mid 2026

[1]TBI = Traumatic brain injury
[2]SUD = Substance use disorder

Pipeline of In House Discovered Programs

Molecule / MoA	Partner	Stage				Milestone
		Discovery	IND Studies	Phase 1	Phase 2a	
Dipraglurant (mGlu5 NAM)		Brain injury recovery - post-stroke / TBI				Ready to start Phase 2a study*
ADX71149 (mGlu2 PAM)		Indication under evaluation				New indication selection
$GABA_B$ PAM	INDIVIOR	Substance use disorders				File IND
$GABA_B$ PAM		Chronic cough				IND enabling studies ready to start*
20% Neurosterix LLC – Advancing a focused CNS Pipeline						
NTX-253 (M4 PAM)		Schizophrenia				Complete Phase 1 Q2 2026
NTX-529 (M4 PAM)		Psychosis / mood related disorders				
NTX-819 (mGlu7 NAM)		Mood disorders				
Multiple undisclosed		CNS				

addex Therapeutics

* Timings subject to financing/partnering
TBI = Traumatic brain injury
NAM = Negative Allosteric Modulator

PTSD = Post-traumatic stress disorder
PAM = Positive Allosteric Modulator

Dipraglurant (mGlu5 NAM) for Brain Injury Recovery Post-Stroke / TBI

Targeting neuroplasticity early in rehabilitation to promote rebuilding of neuronal connections and sensorimotor recovery

Post Stroke / TBI Recovery - Unmet Medical Need & Commercial Opportunity

- Many stroke /TBI patients suffer motor and somatosensory impairment
- Potential chronic disability & low quality of life



- >101 million ischemic stroke survivors worldwide[1]
- >12 million new strokes/yr (1 every 3 seconds)[1]

- Rehabilitation therapies: e.g. physiotherapy, speech, communicatio and cognitive
- Majority never fully recover

- Intense early rehabilitation promotes recovery
- But, no approved drugs to support rehabilitation therapies

Urgent medical need to promote sensorimotor recovery in post-stroke patients

[1]World Stroke Association 2022

addex Therapeutics

mGlu5: An Innovative Target for Brain Injury Recovery

Healthy brain



mGlu5 brain distribution



Good inter & intra-nodal connectivity

mGlu5 NAM supports rebuilding of neuronal connections



Recovery

+ mGlu5 NAM



mGlu5

- Densely expressed in the brain
- Involved in neural plasticity
- Modulates excitation/inhibition equilibrium

Lesion effects:

- Confined neural tissue necrosis
- Network disruption & module segregation
- Imbalance in excitation/inhibition

mGlu5 NAM promotes synaptic plasticity

- Cortical reorganization & new functional pathways (a)
- Connectivity changes toward pre-lesion state (b)
- Restoration of excitation/inhibition equilibrium

addex Therapeutics

Adapted from DOI: 10.3389/fnsys.2021.806544

Preclinical Data: mGlu5 Inhibition Promotes Post-Stroke Recovery



MTEP treatment resulted in a significant recovery of functional control



Dipraglurant significantly restored functional control in a one-week experiment

Dipraglurant enhanced functional brain recovery in a rat model of experimental stroke

From patent application PCT WO2017/171594A1

addex Therapeutics

MRI Imaging Data: Post-Stroke Resting State Functional Connectivity



mGlu5 inhibitors promote intra- and inter-hemispheric connectivity following stroke

https://doi.org/10.1093/brain/awad293

addex Therapeutics

Dipraglurant for Post-Stroke/TBI Recovery - Development Status

- Fast onset of action and short half-life
  - Ideally suited for concurrent dosing with rehabilitation
- Extensively profiled Phase 1 studies
  - 5 studies with >100 patients
  - Including receptor occupancy (PET ligand study)
- Phase 2 studies conducted
  - Safe and well tolerated in patients suffering from neurological disease – Parkinson's disease
  - Mild to moderate CNS type AEs at doses < 200mg
  - 7 PD-LID patient exposed >6 months
- CMC Status
  - >30kg API in stock
  - Drug product available in 50mg and 100mg tablets with placebo
- IP
  - Patent protection through 2037 (without extensions)

First-in-class program for post-stroke recovery ready to start Phase 2

GABAB PAM for Substance Use Disorders (Indivior Partnership)

Going beyond baclofen to treat substance use disorders with improved safety and tolerability

GABAB PAM for Substance Use Disorder

Large market & unmet medical need	➢ High prevalence:1.8% of US population[1] ➢ Current treatments have undesirable side-effects and prone to relapse ➢ Burden to society in US is >$600B annually[2]
Clinically validated MoA	➢ Baclofen (GABAB agonist) used off label for alcohol use disorder ➢ ADX71441 attenuates alcohol self-administration and relapse to alcohol seeking in rats[3] and alcohol consumption in mice[4] ➢ ADX71441 reduces cocaine self-administration in non-human primates[5]
Status of program and near-term milestone	➢ Funded research phase of collaboration completed ➢ Drug candidate successfully completed IND enabling studies ➢ Differentiated leads and backups with robust novel IP potential
Strategic partnership with Indivior	➢ Eligible to receive $330 million in milestones and tiered royalties from high single digits to low double digits

addex Therapeutics

[1]Merikangas et al. 2010
[2]NIDA
[3]Augier et al 2017
[4]Hwa et al 2014
[5]Addex int. report

GABAB PAM for Chronic Cough

Going beyond baclofen to treat cough with improved safety and tolerability

Cough - Unmet Medical Need and Commercial Opportunity

- Chronic cough
  - Lasting > 8 weeks[1]
  - >700 coughs/day
- Multiple comorbidities



- 10% in the general population
- Persists >1 year in 60% of patients

- Ineffective in 30% of patients[3]
- Hindered by side-effect risks

- P2X3 Inhibitors (Phase 3):
  - Ineffective: ~30% of patients
  - Discontinuation: ~20% (taste related side-effects)
- Haduvio (Trevi) – kappa agonist and a mu opioid antagonist (Phase 2)

High unmet medical need for an efficacious and safe treatment of cough

addex Therapeutics

[1] Morice et al. *Eur Respir Rev* 2021
[2] Cough Remedies Market Share, Size and Industry Growth Analysis 2021 - 2026 (industryarc.com)
[3] Ryan *Expert Opin Pharmacother* 2018

Pharmacological Treatment of Chronic Cough – Efficacy vs Tolerability

Use / side-effects	Dextro-metorphan	Opioids	Nalbuphine (Phase 2)	Gabapentin & pregabalin	Amitriptyline	P2X3*	GABAB Agonist Baclofen	GABAB Addex PAM
Treatment type	Chronic	Acute	?	Acute	Acute	Chronic	Chronic+	Chronic
Risk of Abuse	Yes	Yes	No	Yes	Yes	No	No	No
Respiratory	No	Yes	Yes	Yes	Yes	No	Yes	No
Other CNS	Yes	Yes	Yes	Yes	Yes	No	Yes	No
Gastrointestinal	Yes	Yes	No	No	No	No	No	No
Taste-related	No	No	No	No	No	Yes**	No	No

- P2X3 inhibitors
  - *Taste-related side effects observed in up to 97% of patients treated with gefapixant - expected to be less with camlipixant1
  - ** Ineffective in up to 30% of patients due to peripheral MoA
- GABAB agonist baclofen
  - Most patients discontinue due to poor tolerability

GABAB PAM has the potential to offer a best-in-disease efficacy and tolerability profile

addex Therapeutics

[1]Niimi et al. *Allergology International* 2022

GABAB Receptor - Validated Target in Cough

- GABAB receptor
  - Expressed throughout the cough neural circuit
  - Activation reduces neuronal excitability
  - Potential for broad application in cough patients
- Baclofen, an orthosteric agonist
  - Used off-label in patients with chronic cough
  - Clinical studies with cough patients showed efficacy
  - Efficacious in healthy volunteer and multiple preclinical models
- Selective GABAB PAM
  - Differentiated pharmacology
  - Improved efficacy and tolerability demonstrated in preclinical models
  - Absence of receptor desensitization with chronic treatment



The anatomical mediators of cough (1)

GABAB PAM offers potential for improved treatment for cough patients

[1]Mazzone and McGargey *Clin Pharm Ther* 2021

GABAB PAM for Cough – Program Status

- Addex has a range of diverse potent and selective GABAB PAMs that were explored for cough indications
- Clinical candidate selected:
  - Favorable developability
  - Pre-IND activities completed
  - CMC completed
- In vivo proof-of-concept in a broad range of cough models demonstrated
  - Consistent MED of 1 mg/kg and ED_{50} of 6 mg/kg in cough frequency
  - No signs of tolerance after sub-chronic (7-day) treatment
  - Similar to a P2X3 inhibitor
  - No marked changes in respiratory rate, body temperature and growth hormone release up to 60 mg/kg across experiments
- IND enabling studies ready to start*

* Timings subject to financing/partnering

Citric Acid Cough in Guinea Pigs - Total number of coughs











- Compound A results in a dose-dependent reduction in number of coughs (MED 1 mg/kg)
- Compound A reaches maximal effects that are equal or higher than with reference compounds

addex Therapeutics

Citric Acid Cough in Guinea Pigs – Latency to 1st Cough



- Compound A results in a dose-dependent increase in cough latency
- Compound A reaches maximal delays in the onset of cough that are similar or better than reference compounds, except codeine









addex Therapeutics

Citric Acid Cough in Guinea Pigs – Respiratory Rate











- Biomarker of sedation
- Compound A had no effect on respiratory rate at up to 60 mg/kg, while other compounds resulted in marked reduction in respiratory rate at their highest doses

addex Therapeutics

Citric Acid Cough in Guinea Pigs

Cough frequency

Compound	ED_{50} (mg/kg)	Max Efficacy	Max Efficacy*
Compound A	5.96	70%	70%
Nalbuphine	7.57	70%	65%
Orvepitant	14.2	55%	51%
Baclofen	0.93	60%	50%
Codeine	12.6	70%	40%

Latency to 1st cough

Compound	Max Efficacy	Max Efficacy*
Compound A	282	282%
Nalbuphine	182	100%
Orvepitant	240	235%
Baclofen	54	10%
Codeine	357	226%

- Compound A shows better efficacy at the maximal dose free from respiratory side-effects

*the highest dose without effects on respiratory rate

addex Therapeutics

Citric Acid Cough in Guinea Pigs

Pharmacokinetic/pharmacodynamic interaction





Antitussive activity of Compound A shows good PK/PD and correlation between tussive readouts and free plasma/brain concentrations; No such relationship is seen on side-effect related readouts

addex Therapeutics

Citric Acid Cough in Guinea Pigs – Reduction in Body Temperature

- Rodent biomarker of GABAB receptor occupancy in the CNS
- Compound A resulted in a minor (0.7°C) reduction in body temperature only at the highest dose (60 mg/kg), in contract to near 2°C seen with baclofen at 3 mg/kg.
- Compound A is likely to have less CNS receptor occupancy than baclofen – contributing to its better tolerability





Citric Acid Cough in Guinea Pigs – Growth Hormone in Plasma

- Biomarker of GABAB receptor occupancy in the CNS
- Compound A did not increase growth hormone in plasma at up to 60 mg/kg, while baclofen caused more than 2x increases in growth hormone concentration
- Compound A is likely to have less CNS receptor occupancy than baclofen – contributing to its better tolerability





addex Therapeutics

ATP Potentiated Citric Acid Cough in Guinea Pigs

- Compound A appears more potent than P2X3 inhibitor in the ATP – CA cough
- In a follow-up experiment involving co-administration of Compound A and P2X3 inhibitor isobolographic analysis revealed potentiation effect on cough frequency

Total number of coughs



Cough latency



ATP Potentiated Citric Acid Cough in Guinea Pigs

- Both Compound A and P2X3 have no effect on respiratory rate, BT and growth hormone at up to 30 mg/kg
- Tolerability profile of Compound A is similar to that of P2X3 inhibitor, but without any taste-related side-effects



Citric Acid Cough in Guinea Pigs

- Following sub-chronic treatment there were no signs of reduced potency or efficacy
- There were no marked changes in the respiratory rate, body temperature and growth hormone release in animals given Compound A acutely or sub-chronically





Activity of Compound A in a Model of CA Induced Cough in Guinea Pigs: Sub-chronic Treatment

SIDE EFFECTS-RELATED READOUTS







No marked changes in side effect related readouts following sub-chronic administration

addex Therapeutics

Bleomycin Model of IPF Related Exacerbated Cough in Guinea Pigs



Groups
1. Intact controls (n=12)
2. BLM – saline (n=16)
3. BLM – 10 mg/kg (n=16)

Culled on day 7
1. Intact controls (n=6)
2. BLM – saline (n=8)
3. BLM – 10 mg/kg (n=8)

Culled on day 28
1. Intact controls (n=6)
2. BLM – saline (n=8)
3. BLM – 10 mg/kg (n=8)

addex Therapeutics

BLM IPF Model - Effects of Compound A on Cough Frequency



p<0.01,*p<0.001 vs BLM-Vehicle group

- Chronic administration of Compound A resulted in a robust and consistent reduction in BLM-stimulated cough frequency up to the last day of testing on Day 28

BLM IPF Model - Effects of Compound A on Cough Latency



*p<0.05 vs BLM-Vehicle group

- Chronic administration of Compound A resulted in a full reversal of BLM-mediated short latencies to the level of untreated controls between days 14 and 28

BLM IPF Model - Effects of Compound A on Reduction in Body Temperature



- A minimal (-0.4 to -0.7 °C) reduction in body temperature in response to Compound A treatment is indicative of low-moderate central receptor engagement
- Marked (- 2°C) reduction in body temperature was seen with baclofen at > 3 mg/kg

addex Therapeutics

BLM IPF Model - Effects of Compound A on Respiratory Rate

COMPOUND A



BACLOFEN



- Chronic administration of Compound A had no marked impact on the respiratory rate up to Day 28
- Baclofen resulted in marked reduction in respiratory rate at >3 mg/kg

addex Therapeutics

BLM IPF Model: Guinea Pig Lung Histopathology Analysis (Day 7)

Groups Criteria	Intact controls	BLM – Vehicle	BLM – Cpd A
Ashcroft score	2.8	1.7	1.2
% of affected lung	13	11.7	6.7
Final score	42	20.8	10

- Sub-chronic administration of Compound A was associated with markedly lower Ashcroft scores and the percentage of affected lung in comparison to BLM-vehicle and intact controls when assessed at the end of treatment on Day 7



Figure 2: Day 7, *Representative illustrations of Pathological observations in animal from group 1, 2 and 3. RS: Sirus Red (collagen in red), HES: hematoxylin-eosin- saffron.*

BLM IPF Model: Guinea Pig Lung Histopathology Analysis (Day 28)

Groups Criteria	Intact controls	BLM – Vehicle	BLM – Cpd A
Ashcroft score	1.5	2.1	1.4
% of affected lung	9.2	11.3	6.3
Final score	17.5	36.9	10

- Chronic administration of Compound A was associated with markedly lower Ashcroft scores and the percentage of affected lung in comparison to BLM-vehicle and intact controls when assessed at the end of treatment on Day 28



Figure 2: Day 28, *Representative illustrations of Pathological observations in animal from group 1, 2 and 3. RS: Sirus Red (collagen in red), HES: hematoxylin-eosin- saffron.*

BLM IPF Model: Conclusions

- Chronic QD administration of Compound A in BLM-exposed animals:
  - Marked and sustained antitussive effects in cough frequency and latency
  - Lower Ashcroft scores and percentage of affected lung in comparison to BLM exposed animals at Day 7 and Day 28
  - No effects on immune cells, inflammatory and fibrotic biomarkers or tidal volume
- Antitussive effects were observed without marked changes in respiratory rate or body temperature
- These findings suggest that Compound A can be used as an effective and well-tolerated antitussive drug in chronic cough exhibited by IPF patients
- Compound A may deliver disease-modifying effects by reducing lung tissue pathology and slowing the progression of the disease

Effect of Compound A in Citric Acid Induced Cough in NHP & Guinea Pigs



i.v. administration

***p<0.001 vs Veh
***p<0.001 vs Sal
repeated measures ANOVA



p.o. administration

- Compound A showed significant efficacy (63-69% reduction) with p<0.001 in the total number of coughs at 2 mg/kg - equivalent to that shown in guinea pigs

Top-Level Plan for GABAB PAM in Cough

- Clinical candidate selected
  - Reproducible efficacy with good PK/PD in guinea pigs (MED 1 mg/kg)
  - Different TPP available - potential for broad application in cough patients
  - Favourable developability and non-GLP tox studies completed in Rat, NHP & Dog
  - Met ID indicates dog as an outlier -> NHP proposed as a non-rodent tox species in GLP studies
  - >2kg demo-batch available to start IND enabling studies and drug product development
  - Citric acid cough in NHP: robust antitussive efficacy demonstrated

Development Plan



Phase 1 with cough challenge data in cough patients expected mid 2028

20% Equity Interest in Neurosterix

Well funded preclinical portfolio of high value assets

Neurosterix

- Addex spin-out company
  - Series A funding of $65 million in 2024 led by Perceptive Advisors
  - Addex contributed allosteric modulator drug discovery platform and portfolio of preclinical programs
  - Addex received CHF5 million and a 20% equity interest
- High value pipeline advancing to high value milestones:
  - M4 PAM for schizophrenia
    - Clinically validated target
    - IND enabling studies successfully completed
    - Phase 1 started in Q4 2025 and expected to complete in May 2026
  - mGlu7 NAM for mood disorders
    - First-in-class program
    - IND enabling studies ongoing
  - Other discovery programs for neuropsychiatric disorder
    - In lead optimization

Multiple high value programs funded to significant value inflection milestones

Addex Financials and Stock

Financials and Stock

- Cash at December 31, 2025: CHF 1.6M (USD 2.0M)
  - Cash runway through mid 2026
- No debt
- Traded on SIX Swiss Exchange: ADXN (ISIN:CH0029850754)
- ADS representing 120 shares traded on Nasdaq: ADXN (ISIN: US00654J206; CUSIP: 00654J206)
- 151.90 M outstanding shares
  - Armistice Capital LLC – 19.57%*
- 218.65M shares incl. treasury shares (285.19M fully diluted)
  - Management & board holds – 11.99%*
- Analyst coverage:
  - HC Wainwright - Raghuram Selvaraju

addex Therapeutics

* Percentage of ownership calculated based on shares and warrants divided by fully diluted shares

Summary

Multiple high value partnerships	➢ GABAB PAM for substance use disorder (Indivior) candidate selected & IND enabling studies successfully completed ➢ 20% equity interest in Neurosterix (backed by Perceptive Advisors) ➢ Investment in Stalicla, clinical stage precision medicine neurodevelopmental disorder company
In house programs driving future value	➢ Dipraglurant - brain injury recovery Phase 2a ready to start ➢ GABAB PAM for chronic cough ready to start IND enabling studies ➢ ADX71149 (mGlu2PAM) - indication under evaluation
Solid foundation	➢ Partnerships with industry leaders – Indivior ➢ Dual listed SIX Swiss exchange & US Nasdaq ➢ Cash runway through mid 2026
Promising outlook	➢ GABAB PAM cough program – ready to start IND enabling studies ➢ Dipraglurant Phase 2 ready to start Phase 2 in post-stroke/TBI recovery ➢ 20% holding in Neurosterix – Lead program, M4 PAM in Phase 1 expected to complete in May 2026

addex Therapeutics

ALLOSTERIC MODULATORS FOR HUMAN HEALTH

www.addextherapeutics.com